Parkinson's Disease Pipeline Insight 2025: 100+ Pipeline Drugs, Gene, Cell, and Disease-Modifying Strategies Drive Momentum

DelveInsight's "Parkinson's Disease - Pipeline Insight, 2025" surveys a robust and fast-moving pipeline of 100+ investigational therapies spanning small molecules, biologics, gene, and cell therapies. Major developers advancing programs include Roche, Biogen (with Denali), Novartis, Voyager Therapeutics, Eli Lilly, and multiple biotech innovators working on alpha-synuclein, LRRK2, GBA, and other novel targets.

The pipeline's mechanism diversity reflects both symptom management and disease-modifying ambitions: anti-alpha-synuclein approaches (antibodies, ASOs, RNAi), LRRK2 and GBA-targeting small molecules, neuroprotective/metabolic strategies, and increasing activity in AAV and cell-based gene therapies. Recent reviews highlight LRRK2 and alpha-synuclein as leading therapeutic axes and flag growing investment in gene therapy and cell approaches.

With numerous Phase II and Phase III trials active, the field is shifting toward precision-targeted and potentially disease-modifying strategies, though notable mid-stage setbacks (for example, an anti-alpha-synuclein study reported by Roche) underline the development risks ahead. If several late-stage candidates succeed, the Parkinson's treatment landscape could move beyond symptomatic control to therapies that slow or alter disease course.

Interested in learning more about the current treatment landscape and the key drivers shaping the Parkinson's disease pipeline? Click here: https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Parkinson's Disease Pipeline Report
• DelveInsight's Parkinson's disease pipeline analysis depicts a strong space with 80+ active players working to develop 100+ pipeline drugs for Parkinson's disease treatment.
• The leading Parkinson's disease companies include AbbVie, Pharma Two B Ltd., UCB Biopharma, Ventyx Biosciences, FAScinate Therapeutics, Longevity Biotech, Lundbeck A/S, iCamuno Biotherapeutics, Neuropore Therapies, and others are evaluating their lead assets to improve the Parkinson's disease treatment landscape.
• Key Parkinson's disease pipeline therapies in various stages of development include Tavapadon, P2B001, UCB0022, VTX3232, KM-819, LBT-3627, Lu AF-28996, ICA07, NPT1220-478, and others.
• In Aug 2025, Serina Therapeutics announced FDA support to advance SER-252 (POZ-apomorphine) into a registrational study for advanced Parkinson's via the 505(b)(2) NDA pathway.
• In July 2025, NKGen Biotech received FDA authorization for an Expanded Access Program (EAP) to use its NK cell therapy, troculeucel, in multiple neurodegenerative diseases, including Alzheimer's, Parkinson's, ALS, MSA, PSP, FTD, MS, and Lewy Body Dementia, beyond its current Phase 2a trial in moderate-stage Alzheimer's disease.
• In July 2025, the FDA cleared the new Magstim Rapid TMS system for research, clinical use, and treatment of pain. This next-generation non-invasive neuromodulation device supports studies and therapy for conditions including depression, OCD, Alzheimer's, Parkinson's, autism, and stroke, featuring upgraded touchscreen, user-friendly software, and improved data management.
• In June 2025, Capsida Biotherapeutics announced FDA clearance of its IND application for CAP-003, an IV-administered gene therapy for Parkinson's disease with GBA mutations (PD-GBA). This marks Capsida's second wholly owned clinical program using its proprietary BBB-crossing capsid and detargeted gene cargo, manufactured in its GMP facility.
• In May 2025, AskBio Inc., a Bayer subsidiary, announced the publication of full Phase Ib trial results for AB-1005, a GDNF gene therapy for Parkinson's disease, in the journal Movement Disorders.
• In March 2025, MedRhythms announced that MR-005, its neurorehabilitation system designed to support gait rehabilitation and motor function in adults with Parkinson's disease (PD), has been classified as a Class II, Rx-only medical device by the FDA. The system will be marketed under the brand name Movive.
• In March 2025, Medtronic plc, a global leader in healthcare technology, announced the U.S. Food and Drug Administration (FDA) approval of BrainSenseTM Adaptive deep brain stimulation (aDBS) and BrainSenseTM Electrode Identifier (EI). While there is no cure for debilitating neurological conditions like Parkinson's, deep brain stimulation (DBS) has been transforming the lives of patients with Parkinson's and other neurological disorders for over 30 years.

Request a sample and discover the recent breakthroughs happening in the Parkinson's disease pipeline landscape at https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Parkinson's Disease Overview
Parkinson's disease is a progressive neurodegenerative disorder that primarily affects movement control due to the loss of dopamine-producing neurons in a region of the brain called the substantia nigra. It commonly presents with symptoms such as tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Non-motor symptoms like sleep disturbances, mood changes, cognitive decline, and autonomic dysfunction also frequently occur. While the exact cause is unknown, a combination of genetic and environmental factors is believed to contribute. Although there is currently no cure, treatments including medications, physical therapy, and in some cases surgical interventions help manage symptoms and improve quality of life. Research is ongoing to develop disease-modifying therapies aimed at slowing or halting progression.

Find out more about Parkinson's disease medication at https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Parkinson's Disease Treatment Analysis: Drug Profile
Tavapadon: AbbVie
Tavapadon is a selective partial agonist targeting dopamine D1 and D5 receptors, being developed by Cerevel for the treatment of both early- and late-stage Parkinson's disease. Designed as an oral, once-daily medication, tavapadon aims to improve motor symptoms by selectively activating D1/D5 receptor subtypes, thereby enhancing motor function while maintaining a favorable tolerability profile. By specifically stimulating the direct motor pathway, tavapadon potentially offers motor benefits with fewer side effects commonly seen with non-selective dopamine agonists, such as daytime sedation, somnolence, impulse control disorders, and psychotic symptoms like hallucinations.

KM-819: FAScinate Therapeutics
KM-819 is a small molecule inhibitor of FAF1, a proapoptotic protein implicated in degenerative diseases. It has demonstrated strong neuroprotective effects in Parkinson's disease models, and ongoing clinical trials are evaluating its efficacy in human patients. Additionally, KM-819 shows potential for treating other neurodegenerative disorders, including multiple system atrophy (MSA). It has exhibited an excellent safety profile in both long-term animal toxicology studies and completed Phase I clinical trials. Currently, KM-819 is in Phase II clinical trials for Parkinson's disease.

UCB0022: UCB Biopharma
UCB0022 is an oral small molecule developed by UCB Biopharma that acts as a positive allosteric modulator of the dopamine D1 receptor (D1R). Unlike direct agonists, UCB0022 enhances the receptor's response to natural dopamine without activating it independently. This approach aims to improve motor function while reducing the need for high dopamine doses that can cause side effects like dyskinesia linked to excessive D2 receptor activation. Promising preclinical results have led to ongoing Phase II clinical trials assessing UCB0022's safety and efficacy as an adjunct to levodopa in patients with advanced Parkinson's disease.

Learn more about the novel and emerging Parkinson's disease pipeline therapies at https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Parkinson's Disease Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

By Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Scope of the Parkinson's Disease Pipeline Report
• Coverage: Global
• Key Parkinson's Disease Companies: AbbVie, Pharma Two B Ltd., UCB Biopharma, Ventyx Biosciences, FAScinate Therapeutics, Longevity Biotech, Lundbeck A/S, iCamuno Biotherapeutics, Neuropore Therapies, and others.
• Key Parkinson's Disease Pipeline Therapies: Tavapadon, P2B001, UCB0022, VTX3232, KM-819, LBT-3627, Lu AF-28996, ICA07, NPT1220-478, and others.

To dive deep into rich insights for drugs used for Parkinson's disease treatment, visit: https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Parkinson's Disease Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Parkinson's Disease Pipeline Therapeutics
6. Parkinson's Disease Pipeline: Late-Stage Products (Phase III)
7. Parkinson's Disease Pipeline: Mid-Stage Products (Phase II)
8. Parkinson's Disease Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.